Investing in Mah Sing is a better bet and you will not regret. Their venture in to Gloves has tons of credibility.

The demand for glove will continue to soar till year 2027 according to US news.
-------------------------------------------------------------------

1. Allied Market Research (US) estimates that the global disposable gloves market amounted to $6.8 billion in 2019, and is expected to nearly triple to $18.8 billion by 2027.

2. According to Sebastien Lenoble (director of Netherlands-based Shield Scientific) who helps to market gloves have been receiving calls from new customers who are very desperate to get their hands on gloves.

3. Monika Riedel from Austrian company Semperit has also claimed that there is threefold increase in demand for examination gloves, and demand for surgical gloves has also increased significantly.

4. Malaysian manufacturers' association MARGMA, worldwide demand is projected to rise from 296 billion in 2019 to 330 billion this year. From February 2020 to June 2020, manufacturers worked at full capacity but still were not able to meet the need.

5. With raw materials in short supply, production costs are also rising. The shortage of raw material for our nitrile gloves and the disruption to the supply or production of other material such as packaging materials due to the global lockdown, has caused an increase in the production cost.

6. With a daily infections continue to rise in USA. Medical Gloves market is predicted to reach US$70 Billion by 2027. Driven by epidemics and pandemics, the global market for Medical Gloves is projected to reach US$70 billion by 2027, trailing a CAGR of 12.

7. The reason for a high demand of nitrile gloves are not just for medical reason. Disposable gloves are used in varied applications, including, cleanrooms, food and beverage, and industrial and chemical.

In conclusion, the demand for glove will continue to soar till year 2027 according to US news.

SUPERMAX to benefit the most from the surge in ASP
-----------------------------

Reuters headline: “Top Glove warns on deliveries after virus outbreak shuts plants.”

The article’s major concern: “One analyst said Top Glove’s main rivals did not have spare capacity to increase supply to meet a shortfall, saying Hartalega and Supermax are already running at best full utilization rate.” (Note: Reuters’ news was carried by multiple news media.)

The coming 2Q21 earnings of Supermax to be more super than they already would have been.

This shortage will push the ASP higher. It will automatically push the earnings even higher.

Supermax will have more super-earning quarters ahead.

Great article. Thanks for sharing.

Today's closing of RM8.60 will be excellent.

Foreign Funds set to return- to GLOVES

-Budget approved

-NO windfall tax

- Moodin and Company clings on to power.

Its showtime for GLOVES especially the worlds most undervalued stock- SUPERMAX.

Hallelujah !

Moderna’s coronavirus vaccine may not get life back to normal right away
------------------------------------------------------------------
Because it hasn’t yet been proven to prevent the deadly bug from spreading, the company’s top doctor says.

Research has shown that the biotech firm’s shot is effective at preventing people from getting sick with COVID-19, but there’s no hard evidence that it stops them from carrying the virus “transiently” and potentially infecting others who haven’t been vaccinated, according to Dr. Tal Zaks, Moderna’s chief medical officer.

“I think we need to be careful, as we get vaccinated, not to over-interpret the results,” Zaks told Axios in a TV interview released Monday. “When we start the deployment of this vaccine, we will not have sufficient concrete data to prove that this vaccine

https://nypost.com/2020/11/24/moderna-boss-says-covid-shot-not-proven-to-stop-virus-spread/

ASP's to SKYROCKET -Here's a snapshots of what the major news media reported:
---------------------------------------------------------------
Forbes headline: “Major PPE Maker Shuts Factories After Nearly 2,500 Workers Test Positive For Covid-19.” The article’s major concern: “The extent to which the factory closures will further affect the world’s already tight supply of rubber gloves.”

Reuters headline: “Top Glove warns on deliveries after virus outbreak shuts plants.” The article’s major concern: “One analyst said Top Glove’s main rivals did not have spare capacity to increase supply to meet a shortfall, saying Hartalega and Supermax are already running at best full utilization rate.” (Note: Reuters’ news was carried by multiple news media.)

Medicalexpress headline: “World's top surgical glove maker shuts factories due to coronavirus.” The articles’ major concern: “A Malaysian company that is the world's biggest manufacturer of surgical gloves will close over half of its factories after a surge in coronavirus cases …”

CBS headline: “More than 2,400 workers at world's top glove maker test positive for coronavirus.” The article’s major concern: “We expect delays in some deliveries by about two to four weeks, as well as a longer lead time for orders ….”

USNews headline: “Virus Outbreak Delays Production at World's Top Glove Maker.” The article’s major concern: “…the world’s largest maker of rubber gloves, says it expects a two-to-four-week delay in deliveries … raising the possibility of supply disruptions during the pandemic.”

After admitting mistake, AstraZeneca faces difficult questions about its coronavirus vaccine

NEW YORK (NYTIMES) -

Scientists and industry experts said errors and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results.

https://www.straitstimes.com/world/united-states/after-admitting-mistake-astrazeneca-faces-difficult-questions-about-its

Supermax - The leading black horse.

https://klse.i3investor.com/blogs/lkp/2020-11-25-story-h1536556007-Supermax_The_leading_black_horse.jsp

Interesting Article, many thanks for sharing your thoughts. SUPER is without a doubt a thoroughbred.

Supermax Poised to be the Cheapest index linked stock in the world.

The up side for SUPER to the MAX is Amazing.

Just Hold on to this SUPER GEM

INVESTORS will be REWARDED.
-----------------------------------------------------------

Posted by freetospeak > Nov 26, 2020 7:39 AM | Report Abuse

1 qtr earn eps rm1.....

1 qtr earning can reduce super pe to 8

SUPERMAX FAIR VALUE is RM14.60
--------------------------------------
Given it's latest EPS of 30.58 cent, it is highly possible for it achieve the same EPS throughout the Financial Year 2021.
With a conservative estimate that their earning stay the same EPS 30.58 x 4quarters = RM1.22
With an EPS of RM1.22
If we assume
PE10 = Share Price is RM12.20
PE12 = Share Price is RM14.64

KUALA LUMPUR, Nov 24 — Voting on Budget 2021 could be delayed a week from Thursday, said government sources.-.

The delay could provide Prime Minister Tan Sri Muhyiddin Yassin’s government time to negotiate support for Budget 2021 or adjust the federal spending plan to win over critics.

Since its tabling on November 6, both government and Opposition lawmakers have questioned the allocations and priorities in Budget 2021 despite the Yang diPertuan Agong’s repeated advice for them to support this in the interests of the country.

Among their demands include an extended loan moratorium, increased withdrawals from statutory retirement savings, and larger cash handouts.

The more prominent MPs who have indicated their reluctance to support the budget include former prime minister Datuk Seri Najib Razak and Gua Musang MP Tan Sri Tengku Razaleigh Hamzah.

All the people behind the company are dodgy to say the least. They managed to rope in a dodgy Promoter aka Ky but decided to take profit like speedy Gonzales and left many ATians high and dry. Always get in with your eyes wide open.
Cheers folks.

Moderna Chief Medical Officer Tal Zaks told Axios that the public should not "over-interpret" the vaccine trial results to assume life could go back to normal after adults are vaccinated.

Zaks warned that the trial results show that the vaccine can prevent someone from getting sick or "severely sick," as Zaks puts it, from COVID-19, however, the results don't show that the vaccine prevents transmission of the virus.

"They do not show that they prevent you from potentially carrying this virus transiently and infecting others," Zaks said in an interview for "Axios," the outlet's show on HBO.

Zaks added: "When we start the deployment of this vaccine we will NOT have sufficient concrete data to prove that this vaccine reduces transmission."

https://klse.i3investor.com/blogs/koonyewyinblog/2020-11-24-story-h1536584031-Supermax_s_easily_achievable_target_price_Koon_Yew_Yin.jsp

On the closing prices at cut-off date, SUPERMX was ranked22nd by market cap, qualifying it for inclusioni nto the FBMKLCI
----------------------------------------------------------------------------
FTSE Russell is due to announce the results of the final semi-annual review for 2020 of the FTSE Bursa Malaysia Index series after business close on Thursday, 3rd December. Decision will be based on yesterday’s closing data. We expect KLCC (OP; TP: RM8.20) to be edged out from the FBMKLCI, being the smallest market cap constituent, by SUPERMX (OP; TP: RM12.00) coming in as the largest non-constituent. SUPERMX which is the market’s 22nd largest by market cap, cleared the threshold of 25th as a condition for entry. The changes would see the rubber glove sector’s weight increase from 11.7% currently to about 14.3% and the FBMKLCI FY21E EPS enhanced marginally by about 2.4%.

Constituent changes will take effect after the close of business on Friday 18th December and the updated FBM series constituents will be reflected in the indices at the start of trading on Monday, 21st December.

Supermax which business module is OBM in nature may be able to benefit from this ASP hike.
Given it's latest EPS of 30.58 cent, it is highly possible for it achieve the same EPS throughout the Financial Year 2021.
With a conservative estimate that their earning stay the same EPS 30.58 x 4quarters = RM1.22
With an EPS of RM1.22
If we assume
PE10 = Share Price is RM12.20
PE15 = Share Price is RM18.30

While other OEM glove manufacturer if i employ the same assumptions

Hartalega latest quarter EPS of 15.95 cent,
Hartalega has previously informed there will be more than 30% increase in ASP for it's next quarter which may translate to a possible
earning of EPS 27.6 cent
Thus trailing 4 quarter EPS may achieve RM0.9695
If we assume,
PE10 = 9.69
PE15 = 14.54

Kossan latest quarter EPS of 13.60 cent,
Kossan has previously informed there will be more than 30% increase in ASP for it's next quarter which may translate to a possible
earning of EPS 25 cent
Thus trailing 4 quarter EPS may achieve RM0.886
If we assume,
PE10 = 8.86
PE15 = 13.20
Kossan

Topglov latest quarter EPS of 15.95 cent,
Topglov coming quarter is estimate to achieve 2billion which will give an EPS of 0.244 if we factor the latest news on the closure of
factory it was estimated to affect their whole year profit by a meager 1.9%
Thus trailing 4 quarter EPS may achieve RM0.850
If we assume,
PE10 = 8.50
PE15 = 12.75

From the above
Supermax seems to have the best upside movement in mid to long terms.

TY YAP favouring SUPERMAX- And rightly so.

https://klse.i3investor.com/blogs/glove2020covid/2020-11-23-story-h1536581016-Top_glove_s_situations_may_benefit_to_all_other_Gloves_Manufacturer.jsp

Supermax is the best performer

https://koonyewyin.com/2020/11/23/supermax-is-the-best-performer/

LATEST NEWS- NO WINDFALL TAX as it is COUNTER PRODUCTIVE
---------------------------------------------------
The government decided no windfall tax will be imposed on glove manufacturers to avoid potential “opportunity costs/losses” such as glove manufacturing companies investing overseas instead of in Malaysia, and sending wrong signal to existing and potential investors in other industries.

The RM400mil contributions by glove manufacturers as announced in Budget 2021 are voluntary and are on top of the glove manufacturers’ record corporate income taxes.

These were among the key points during a post-Budget 2021 dialogue with Datuk Seri Tengku Zafrul Tengku Abdul Aziz last Friday.

Many news are showing countries like USA are running out of gloves and have to purchase even more to overcome the incoming shortage.
---------------------------------------
Glove manufacturers have to put in an even more extra hours to make much more gloves for other countries demand. More and more glove manufacturers are also popping up in order to meet the demand of other countries. Some existing glove manufacturers are also planning increase their lines in order to produce more gloves.

What does this mean for the glove counter share price?

One word. Upward.

Why?

Why the race to find Covid-19 vaccines is FAR FROM OVER.
-----------------------------------------------------
Extracted from The Guardian. UK- 22nd Nov 2020

While everyone celebrated this month’s news that not one but two experimental vaccines against Covid-19 have proved at least 90% effective at preventing disease in late-stage clinical trials, research into understanding how the Sars-CoV-2 virus, which causes Covid-19, interacts with the human immune system never paused.

There are plenty of questions still not answered about the Pfizer/BioNTech and Moderna vaccines:

1- How well will they protect the elderly, for example, and how long for?

2- Which aspects of the immune response that they elicit are protective and which aren’t?

3- Can even better results be achieved, with vaccines that target different parts of the immune system?

4- How long will the immunity last ?

5- Is it safe ?

MS Health Care -to Manufacture of GLOVES- OBM

https://www.thestar.com.my/metro/metro-news/2020/11/21/mah-sings-next-venture-glove-production

Mah Sing’s next venture: Glove production
-------------------------------------------
Saturday, 21 Nov 2020

“FORTY-ONE years ago, we started our plastics business and today we are one of the biggest high-tech plastic product manufacturer and one of the largest plastic pallets producer in Malaysia, ” said Mah Sing founder and group managing director Tan Sri Datuk Seri Leong Hoy Kum.

“We started our first property project 26 years ago and now we are a well-established property player with 50 projects.

“In 2020, we started our new venture into gloves and we target to be one of the top five producers in Malaysia in the future. Now, Mah Sing has its presence in property, plastics and glove manufacturing businesses.”

• Incepted in 1979: 41 years of manufacturing experience.

• Four factories: Two in Malaysia, two in Indonesia.

• Largest clamping force machines in South-East Asia: 75 injection moulding machines with up to 4,000 tonnes clamping force.

• RM16.5mil invested in automation of production lines in Malaysia.

• Export market to 45 countries: 40% of Malaysian sales and revenue derived from export.

• MNC clientele in key industries including food & beverages, electronic & electrical, automotive, healthcare, petrochemical industries, plantation & oleochemicals and pharmaceutical.

• Remaining landbank of 811ha with remaining gross development value and unbilled sales totalling approximately RM24.64bil (as at June 30,2020).

• Continue to focus on providing affordably-priced homes of good quality with 91% of the group’s target sales in 2020 from residential properties priced below RM700,000.

Mah Sing enters new period of growth in proposed glove manufacturing and other medical device products

• First gloves manufacturing factory in Kapar, Klang – 12 new production lines with maximum production capacity up to 3.68 billion pieces of gloves per annum in Phase 1.

• Plan to start proposed glove production in April 2021 with ready factory for installation of glove dipping machinery.

• Targets expansion of 12 additional new production lines in Phase 2 to increase capacity up to another 3.68 billion pieces of gloves per annum if demand exceeds supply.

• Aims to be the top five producers in Malaysia, targets gradual expansion up to 100 lines, potentially producing up to 30 billion pieces if demand permits.

At this juncture, Mah Sing Healthcare has secured letters of intent from several prospective customers and the cumulative indicative orders have already exceeded the estimated maximum capacity for both phases of the Kapar factory.

If demand permits, Mah Sing Healthcare will gradually expand up to 100 production lines as part of future expansion plans. These 100 production lines could potentially produce approximately 30 plus billion pieces of gloves per annum.

As the Kapar factory is expected to start its operation with six production lines as early as 2Q 2021, the group is in a good position to take advantage of the high spot price of gloves.

Mah Sing expects the proposed glove manufacturing business to generate sales for the group relatively quickly with the projected contribution estimated to come in as early as 2Q 2021.

The new proposed gloves business, which predominantly targets the export market, will allow Mah Sing to ride on the booming glove-manufacturing segment and further strengthen its manufacturing division, which is currently focusing on plastics business.

This is expected to provide the group access to the global market and generate more recurring and steady income for the group. This will be a good complement to the property business which focused on the domestic market, and more cyclical in nature.

The group is also pleased to note the recent positive news flow regarding a potential vaccine for the pandemic.

Notwithstanding a viable vaccine for mass use being available, Mah Sing believes the demand for gloves is expected to persist post-pandemic, underpinned by stricter regulations and the increase in awareness of the importance of hygienic practices, especially in emerging markets where the glove consumption per capita is still low as compared with developed countries, which signals more room for long-te

Should you rush to get a COVID-19 vaccination? One specialist in Japan says he won't because its SAFETY NOT GUARANTEED AT ALL

------------------------------------------------------
November 20, 2020 (Mainichi Japan)

Two major U.S. pharmaceutical companies racing to develop novel coronavirus vaccines have announced that their vaccines have been confirmed to be over 90% effective. But Masayuki Miyasaka, a leading immunologist at Osaka University, told the Mainichi Shimbun in a recent interview that even after these vaccines become available, he does not plan to receive them for the time being.

At a meeting of the Committee on Health, Labor and Welfare of Japan's House of Representatives on Nov. 17, Miyasaka stated, "There's no doubt that their effectiveness is quite high, but their SAFETY IS NOT GURANTEED AT ALL," sounding a word of caution about expectations for the vaccines.


https://mainichi.jp/english/articles/20201120/p2a/00m/0na/008000c

Demand for GLOVES to sustain in the long term due to the following reasons:-
------------------------------------------------------------------

1-Takes time for vaccine to reach to the masses

2-Effectiveness still questinable.

3-Antibody might only last a year, the need for annual vaccination.

4-Anti Vaccine ( Anti Vaxxers) on the rise in Europe and USA.

5- Covid-19 mutations may render Vaccines ineffective.


Given the above, the imminent rollout of VACCINES will greatly boost the usage of disposable GLOVES.

Long Term prospects for the GLOVE industry is BRIGHT- A higher PE valuation is justified.

@Agjl- Bro its a buy call by CIMB. Hope I have answered your question- The catalyst remark is my opinion fyi. Thanks.

SUPERMAX Upgraded by CIMB- A BUY CALL- TP-RM13.20

The CATALYST- A NEW COMPONENT KLCI COMPOSIT STOCK

---------------------------------------------------------------------

Source : CIMB

Stock : SUPERMX

Price Target : 13.20

Price Call : BUY

Last Price : 8.28

Upside/Downside : +4.92 (59.42%)


CATALYST. : New KLCI Index STOCK

@lovetze- fully agree with you & well said.

At the end of the day, experienced investors will judge based on profit and foreseeable positive growth prospect. History repeats itself. The pharmaceutical companies will probably face another problem, which is when vaccine is approved for emergency use, will the citizens trust and accept it? If not, the pandemic will just continue to surge until herd immunity is reached or people will just treat it as a new norm and get used to it, wearing face masks, and gloves.

Plus, currently, the pandemic is mutating continuously, which means the vaccine may not be effective after a short period of time. Do think about it, sometimes, it's just a matter of time for the truth to prevail, think about it, don't be manipulated emotionally by short term waves. Take care and stay safe.

Todays surge and maintain above RM8-00 will confirm SUPERMAX's entry to the prestigious KLCI composite index. That when there will be a massive demand for SUPER's shares come December.
Funds will be scrambling for it.

SUPER 's valuation is the cheapest among the BIG4.

A TP of RM12-00 is achievable by Jan 2021.

Be patient folks- SUPER won't let you down.

MAH SING set to be a SUPER stock.
------------------------------------------
TS Leong said Mah Sing’s glove business will be primarily be managed by a professional team with experience in glove manufacturing.

He said Mah Sing will be able to tap into the expertise and know-how of its regional plastics business in order to synergize with the gloves business.

No worries. The Horse always delivers and sings as well.

Now Mah Sing is into Vaccines.

Gloves+Vaccines+Property+Plastics+Construction

2 workers to produce a million pieces of rubber gloves will be reduced significantly.
-------------------------------------------------------------------------
In an exclusive interview with The Edge, its founder and group CEO Tan Sri Leong Hoy Kum says that by using automation, the requirement of two workers to produce a million pieces of rubber gloves will be reduced significantly.


“We are at about two workers per million pieces for a start. Eventually, we will reduce the number of workers required to produce the quantity as automation kicks in. In other words, to produce more than three billion pieces a year, we will only have to recruit a workforce of about 600,” he says.

Taking the first phase production capacity target of 3.68 billion pieces a year, if Mah Sing were to hire 600 workers, each of them would be able to produce 6.1 million pieces of rubber gloves a year with a high level of automation, instead of about 500,000 pieces annually.

The Lancet’s editor-in-chief Richard Horton's interesting comments on Pfizer
------------------------------------
The realization should be arriving that public trust may have never been a primary goal of vaccine-makers. Science™ regularly takes a backseat to profits and ethics [see Pfizer hit with $2.3B largest criminal fraud fine in history by Justice Department]. And even when proper science should be followed, it is often sidestepped. Regularly failing to use inert placebos during vaccine trials, using trial designs with obscenely short observation windows to monitor serious adverse events, refusing to conduct vaccinated vs unvaccinated trials to compare total health outcomes and deep conflicts of interest are all in a day’s work for vaccine makers.

Mah Sing Group Bhd is set to commence glove production in April 2021.

In a statement today, Mah Sing said it has commenced additional piling works to accommodate 12 units of new, high-speed glove dipping machines at its glove manufacturing factory in Kapar, Klang, to meet its targeted production date.

It said the piling works are expected to be completed by November 2020, to be immediately followed by installation of the machinery.

These 12 production lines are Phase 1 of Mah Sing’s diversification into gloves and have a maximum production capacity of up to 3.68 billion pieces of gloves per annum.

Mah Sing founder and group managing director Tan Sri Leong Hoy Kum said similar to its property development’s fast turnaround business model, the firm is fast-tracking its diversification into gloves.

He said the factory has a suitable roof height to house mega machines.

“We have also secured supply of both nitrile-butadiene rubber and latex raw materials, and should be able to quickly meet [the] demand of our customers.

“We are targeting production by as early as April 2021,” said Leong.

Leong said Mah Sing’s glove business will be primarily be managed by a professional team with experience in glove manufacturing.

He said Mah Sing will be able to tap into the expertise and know-how of its regional plastics business in order to synergize with the gloves business.

TP of RM2.80 in April next year when production starts.

Heard MS is into Vaccines as well. Hoseh!

Covid-19: RHB says vaccine deployment could generate demand for up to 18 billion pieces of gloves a year.

MS venture in to Gloves will prove lucrative.

theedgemarkets.com

November 19, 2020 14:20 pm +08

@Laychee- Mah Sing is a very respectable and well run company . Their venture into Gloves is genuine unlike some other counters that are dubious.

Time will tell.

Just my 2 cents.

@NPRA1985. Many thanks for the clarification.

Sinopharm JV with GI Healthcare to sponsor 10,000 doses to Frontliners.

Mah Sing involved via GI Healthcare?

KUALA LUMPUR (Nov 17): China National Pharmaceutical Group (Sinopharm), through GI Healthcare Resources Sdn Bhd — a joint-venture company (JVCo) with local investors — has agreed to sponsor 10,000 doses of the former's Covid-19 vaccine for Malaysian frontliners.

The sponsorship was agreed upon yesterday via a meeting between Malaysian officials, led by Home Minister Datuk Seri Hamzah Zainuddin and Health Minister Datuk Dr Adham Baba, and Sinopharm's chairman Liu Jingzhen via video conferencing.

Meanwhile, GI Healthcare Resources was represented by Tan Sri Lim Yew Loong, Tan Sri Leong Hoy Kum, Sim Guan Yu and Rosli Dahlan as its advisers while Liu represented the firm in the video conference.

Folks , MAHSING is a better bet and you won't regret, a company with integrity, financial strength and realistic in their timeframe to produce gloves in April.

Just my 2 cents.

GLOVES are still the best sector to invest in.
"Vaccine counter" are just HYPE as margins are low and competitive.
Other sectors will take a mighty long time to recover. The recovery play may backfire.
Some may end up "bankrupt" or rather may not recover.
The Big 4 will be the most profitable for the next 2 years or so, particularly SUERMAX due to its fantastic business model.
Vaccine is not a CURE , just a PREVENTIVE measure as immunity may last up to a year.
The huge demand for GLOVES will always prevail post COVID- as health awareness/healthcare is heightened across many sectors.

Be patient Folks.

Interesting article. Good work . Thanks !

Covid-19 vaccine may not give everyone the same degree of protection, Fauci says
-------------------------------------------------------
From CNN’s Lauren Mascarenhas

A Covid-19 vaccine may not give everyone the same degree of protection against the virus, Dr. Anthony Fauci said Tuesday. “It isn't necessarily effective for every single person, so you don't know the degree to which you're protected,” Fauci said during a Spectrum News interview. Makers of two coronavirus vaccine candidates say they are more than 90% effective in preliminary data.

“A vaccine could prevent you from getting sick, but not necessarily prevent you from being infected,” Fauci added. “Although you're vaccinated and protected from illness, you might be infected and could conceivably transmit the infection to someone else.”

Once vaccinated, reasonably healthy people will be able to cut back on some of the more stringent public health measures, said Fauci, director of the National Institute of Allergy and Infectious Diseases. “But you don't want to abandon them completely and put yourself and your family at risk,” he said. Fauci added that people should look at a coronavirus vaccine as just one tool in an “armamentarium of prevention.”

Uncle KYY want to collect at below 15 sen.

AT Systematization is losing support - Koon Yew Yin
Author: Koon Yew Yin | Publish date: Tue, 17 Nov 2020, 7:27 PM

Recently my friend David Loh took me to visit AT Glove factory in Chemor, Perak which is less than 10 km from my house. He circulated the photo showing 2 of us in front of the company sign board. As a result, many investors many investors started to buy ATS shares aggressively. I have posted 2 buy recommendation articles and the big players pushed up the share price from 10 sen to peak at 30 sen within 2 weeks with daily traded volume exceeding 2 billion shares as shown on the price chart below. All my readers would have made some profit so quickly.

Based on the trading volume and the falling of the share price, it looks like the big players are not supporting the share price any more. Today it dropped 1.5 sen to close at 24.5 sen with a reduced volume of 1.22 billion shares traded. This is a sign of weakness in the share price; so be careful.

This morning before the stock market opens, I WhatsApp to all the people on my contact list that I will be selling my AT shares to buy Supermax. My purpose of writing this article is to forewarn all my readers to be careful because the company has not produced any glove yet and it has been losing money in the last 7 quarters.

Uncle Upgraded SUPERMAX from Lame Duck To SUPER underrated stock.

By Koon Yew Yin Posted on November 17, 2020
---------------------------------------------------------
Due to the Covid 19 pandemic the demand for medical gloves far exceeded supply. As a result, all the glove makers can easily increase their selling prices to make more and more profit.

Supermax reported 100% profit increase from its previous quarter ending June. Its 1st quarter ending Sept EPS was 30.58 sen. Its previous quarter EPS was 15.29 sen.

Assuming Supermax do not increase its selling price for its gloves in the whole financial year, its annual profit will be 30.58 X 4 = Rm 1.22. Based on P/E 15 its share price should be Rm 18.3.

To be more conservative and extra safe, I assume that Supermax do not increase its selling price for its gloves for the whole year and its share price is selling at P/E 10, its share price should be 30.58 X 4 quarters X PE 10 = Rm 12.20.

Investors with good foresight should be able to foresee that its 2ndquarter profit ending December should be more than 30.58 X 2 = 61.2 sen. The company will announce its 2nd quarter profit in January, about 2 months from now.

Supermax is the most underrated super glove stock.

Spot-on lah Bro. I believe
-----------------
Posted by Ibelieve > Nov 17, 2020 3:26 PM | Report Abuse

I say today close 8.00, who's with me?

The vaccine is not a silver bullet.

Realistically, it may help to control or reduce the Covid cases but Covid is here to stay. There are still many unanswered questions as to whether how many asymptomatic cases detected in the test group, (and the danger is that Covid can spread quietly unlike SARS, H1N1, etc), whether it induce protection on different ethnic group, gender, age (as in many cases it is harder to induce immune response in older people which are at highest risk), what is the degradation rate of the vaccine efficacy (and for your info, flu vaccine efficacy is merely 40% to 60% and it normally lasted around 4 months which is good enough for winter or flu season but Covid linger throughout the year).

Adverse vaccine news will soon come after detail study and peer review because many questions cannot be addressed in such a such time without deliberate long term study. And, realistically, maybe average 50% world population will take vaccine, and no more than that. To-date, what you are being fed are sales-pitch by the big pharma, like a miracle drug in the market which everyone is hoping for but only to be disappointed again and again.

Covid is here to stay and impose more realistic measure to control the widespread. Vaccine alone is not the answer. It is just human nature believing that there is a miracle discovery that can resolve their problem just like that.

VACCINE WILL NOT BE ENOUGH TO STOP PANDEMIC, SAYS WHO CHIEF
-----------------------------------------------------------
AFP |Monday

GENEVA - The head of the World Health Organization said Monday that a vaccine would not by itself stop the coronavirus pandemic.

The pandemic is raging months after it broke out, with infections soaring past 54 million and claiming more than 1.3 million lives.

"A vaccine will complement the other tools we have, not replace them," director-general Tedros Adhanom Ghebreyesus said. "A vaccine on its own will not end the pandemic."

The WHO's figures for Saturday showed that 660,905 coronavirus cases were reported to the UN health agency, setting a new high water mark.

That number, and the 645,410 registered on Friday, surpassed the previous daily record high of 614,013 recorded on 7 November.

Tedros said that supplies of the vaccine would initially be restricted, with "health workers, older people and other at-risk populations (to) be prioritised. That will hopefully reduce the number of deaths and enable the health systems to cope."

But he warned: "That will still leave the virus with a lot of room to move. Surveillance will need to continue, people will still need to be tested, isolated and cared for, contacts will still need to be traced... and individuals will still need to be cared for."